US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug - Reuters
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"The public caught wind of the FDA announcement... which has triggered a deluge of patient requests."
— Daniel King , Academic
"Doubling survival compared to best available chemotherapy is a big deal."
— Gulam Manji , Academic
"Patients are already aware of the press release and are already calling."
— Vincent Chung , Academic
Key People
Former US Senator diagnosed with Stage 4 pancreatic cancer.
Medical oncologist at the Zuckerberg Cancer Center of Northwell Health.
Co-director of the pancreas center at Columbia/New York-Presbyterian.
CEO of Revolution Medicines.
Pancreas cancer specialist at City of Hope.
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNV2FXR19tUWxiQ2RMdWp5SHJZUFlpSEUtamdIMXdReTd4UzV0Zm0xODZCeGE0bEt4Nmd2MVV6akl6OGtQdVVwNTlEczIwcHVhVGNHVVplMUROQUZoUTFKcHI1ajY1Y3UydGZsZGtsM3duc3BDeDlWQl9LaGtaNFgtMk1LbWcwTXlkVEpIOEMtTGppOTFJMVBPX3RnS0xOaFR1ekhyWlhHMTlLYWplclF4LTFvd3NFWC02V2NrOE9VQzNtX0R0RmJz?oc=5" target="_blank">US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug</a> <font color="#6f6f6f">Reuters</font>
Medscape reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, highlighting the FDA's recent approval for expanded access.
Medscape discusses the urgency among U.S. cancer clinics to provide patients with access to Revolution Medicines' experimental drug daraxonrasib, following the FDA's approval for expanded access.
U.S. cancer centers are urgently enrolling patients in an early access program for Revolution Medicines' experimental drug daraxonrasib, following its FDA-approved expanded access program on May 1, 2026.
Medscape discusses the urgency among U.S. cancer clinics to provide patients with access to Revolution Medicines' experimental drug daraxonrasib, following the FDA's approval for expanded access.
Yahoo News Malaysia reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, following the FDA's recent approval for expanded access.
Medscape reports on the challenges faced by U.S. cancer clinics in accessing Revolution Medicines' experimental drug daraxonrasib, following the FDA's recent approval for expanded access.
Similar Stories
Related coverage based on topic and tags
US FDA expands use of Novartis drug for chronic skin condition - Reuters
US FDA expands use of Novartis drug for chronic skin condition Reuters
October 7, 2026 at 04:51 PMHalozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme wins court order to block Merck's injected Keytruda in select European markets Reuters
October 7, 2026 at 05:03 PMUS FDA flags four deaths in Newron's schizophrenia drug studies - Reuters
US FDA flags four deaths in Newron's schizophrenia drug studies Reuters
October 8, 2026 at 05:47 PMUS health secretary Kennedy launches new push on vaccine injuries - Reuters
US health secretary Kennedy launches new push on vaccine injuries Reuters
October 8, 2026 at 09:59 PMPharma lobby sues Trump administration over Medicare drug price cuts - Reuters
Pharma lobby sues Trump administration over Medicare drug price cuts Reuters
October 7, 2026 at 05:08 PMUS appeals court weighs block on Kennedy's vaccine panel appointments - Reuters
US appeals court weighs block on Kennedy's vaccine panel appointments Reuters
October 6, 2026 at 06:41 PM